Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$1,566,653.00
Nov 1, 2017
Essential Skills for Aboriginal Business
14 14302111
$2,006,850.00
Nov 1, 2017
Essential Skills in a Digital World
14 14920532
$1,561,313.00
Nov 1, 2017
Lead Up
14 1509143
$934,972.00
Nov 1, 2017
YouThExperts
14 1509148
$30,000.00
Nov 1, 2017
$500,000.00
Nov 1, 2017
For-profit organization
Development of new synthetic process for lenalidomide and novel formulations for sustained release tablet
897119
This collaborative project between AC Pharmaceuticals Co., Ltd. in the city of Guangzhou, Guangdong Province, China and TC Scientific Inc. in Edmonton, Alberta, Canada, is to develop lenalidomide sustained-release tablets for the treatment of myelodysplastic syndromes (MDS). TC Scientific Inc. will develop new synthetic routes for lenalidomide and a production process that will be substantially less expensive to execute. The new process will avoid use of strong oxidizing agents and expensive reagents and will also reduce the generation of toxic waste by using less toxic reagents.